TR200000415T2 - Prostat kanserinin tedavi edilmesi için birleşimler. - Google Patents

Prostat kanserinin tedavi edilmesi için birleşimler.

Info

Publication number
TR200000415T2
TR200000415T2 TR2000/00415T TR200000415T TR200000415T2 TR 200000415 T2 TR200000415 T2 TR 200000415T2 TR 2000/00415 T TR2000/00415 T TR 2000/00415T TR 200000415 T TR200000415 T TR 200000415T TR 200000415 T2 TR200000415 T2 TR 200000415T2
Authority
TR
Turkey
Prior art keywords
prostate cancer
combinations
treat prostate
tyrosine kinase
kinase inhibitor
Prior art date
Application number
TR2000/00415T
Other languages
English (en)
Inventor
A. Dionne Craig
Isaacs John
L. Vaught Jeffry
Original Assignee
Cephalon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22000842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000415(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc. filed Critical Cephalon Inc.
Publication of TR200000415T2 publication Critical patent/TR200000415T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Prostat kanserinin, bir indolokarbazol olarak bir tirosin kinaz önleyiciyle ve bir kimyasal hadim etme madesinin birlikte uygulanmasiyla tedavi edilmesi için bir yöntem anlatilir. Bir tirosin kinaz önleyici ve bir kimyasal hadim etme maddesi içeren bir bilesik de ayrica anlatilir.
TR2000/00415T 1997-08-15 1998-08-13 Prostat kanserinin tedavi edilmesi için birleşimler. TR200000415T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5589197P 1997-08-15 1997-08-15

Publications (1)

Publication Number Publication Date
TR200000415T2 true TR200000415T2 (tr) 2000-08-21

Family

ID=22000842

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00415T TR200000415T2 (tr) 1997-08-15 1998-08-13 Prostat kanserinin tedavi edilmesi için birleşimler.

Country Status (22)

Country Link
US (1) US5985877A (tr)
EP (1) EP1011648B2 (tr)
JP (1) JP2001515032A (tr)
KR (1) KR100612161B1 (tr)
CN (1) CN1147317C (tr)
AT (1) ATE208210T1 (tr)
AU (1) AU737092B2 (tr)
BR (1) BR9812122A (tr)
CA (1) CA2299471C (tr)
CZ (1) CZ297198B6 (tr)
DE (1) DE69802422T3 (tr)
DK (1) DK1011648T4 (tr)
EA (1) EA002525B1 (tr)
ES (1) ES2163293T5 (tr)
HU (1) HUP0003194A3 (tr)
NO (1) NO325526B1 (tr)
NZ (2) NZ502646A (tr)
PL (1) PL193375B1 (tr)
PT (1) PT1011648E (tr)
TR (1) TR200000415T2 (tr)
UA (1) UA61970C2 (tr)
WO (1) WO1999008668A2 (tr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020034A1 (en) * 1998-10-08 2000-04-13 Takeda Chemical Industries, Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independent cancer
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
SK14632003A3 (sk) * 2001-05-08 2004-03-02 Merck Patent Gmbh Kombinovaná terapia pri použití anti-EGFR protilátok a antihormonálnych činidiel
SE0101697D0 (sv) * 2001-05-14 2001-05-14 Astrazeneca Ab Pharmaceutical combination
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
EP1424080B1 (en) * 2001-08-10 2011-02-16 Takeda Pharmaceutical Company Limited Gnrh agonist combination drugs
CN100488981C (zh) * 2001-08-24 2009-05-20 维多利亚大学创新和发展公司 含有蛋白酶激活序列的气单胞菌溶素原及其应用
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
CA2611839C (en) 2005-06-14 2016-02-02 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007092453A2 (en) * 2006-02-03 2007-08-16 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
KR101314362B1 (ko) 2006-08-28 2013-10-10 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
US20090130195A1 (en) * 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
NZ731881A (en) 2012-07-25 2022-07-29 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
SI3333191T1 (sl) 2014-12-11 2021-03-31 Pierre Fabre Medicament Proti C10ORF54 protitelesa in uporaba le-teh
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
US10736972B2 (en) * 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
BR112019024717A2 (pt) 2017-05-25 2020-06-09 Univ Cornell nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP7768666B2 (ja) 2017-05-31 2025-11-12 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
CN121248782A (zh) 2017-06-06 2026-01-02 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
RU2667906C1 (ru) * 2017-09-11 2018-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) † 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4923986A (en) † 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5461146A (en) † 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE69409641T2 (de) * 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
SE506019C2 (sv) * 1994-05-17 1997-11-03 Forskarpatent I Linkoeping Ab Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
GB9508538D0 (en) † 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5659407A (en) * 1995-06-06 1997-08-19 Apple Computer, Inc. Method and system for rendering achromatic image data for image output devices
KR20000065227A (ko) † 1996-07-19 2000-11-06 다께다 구니오 복소환 화합물, 그의 제조방법 및 용도

Also Published As

Publication number Publication date
CA2299471A1 (en) 1999-02-25
CN1147317C (zh) 2004-04-28
CA2299471C (en) 2007-12-18
PT1011648E (pt) 2002-03-28
DK1011648T3 (da) 2001-12-27
HK1028565A1 (en) 2001-02-23
KR20010022878A (ko) 2001-03-26
HUP0003194A3 (en) 2003-03-28
EA002525B1 (ru) 2002-06-27
US5985877A (en) 1999-11-16
NZ502646A (en) 2002-04-26
AU737092B2 (en) 2001-08-09
UA61970C2 (en) 2003-12-15
ES2163293T5 (es) 2006-01-16
EP1011648A2 (en) 2000-06-28
DE69802422T2 (de) 2002-07-11
ATE208210T1 (de) 2001-11-15
WO1999008668A3 (en) 1999-04-15
NO325526B1 (no) 2008-06-02
EP1011648B1 (en) 2001-11-07
NZ517497A (en) 2004-11-26
WO1999008668A2 (en) 1999-02-25
ES2163293T3 (es) 2002-01-16
DE69802422D1 (de) 2001-12-13
CZ297198B6 (cs) 2006-09-13
PL338885A1 (en) 2000-11-20
NO20000732D0 (no) 2000-02-14
NO20000732L (no) 2000-03-28
AU9019298A (en) 1999-03-08
EA200000220A1 (ru) 2000-10-30
BR9812122A (pt) 2000-07-18
JP2001515032A (ja) 2001-09-18
DE69802422T3 (de) 2005-12-29
EP1011648B2 (en) 2005-07-20
KR100612161B1 (ko) 2006-08-14
PL193375B1 (pl) 2007-02-28
CN1268061A (zh) 2000-09-27
DK1011648T4 (da) 2005-10-24
HUP0003194A2 (hu) 2001-07-30
CZ2000469A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
TR200000415T2 (tr) Prostat kanserinin tedavi edilmesi için birleşimler.
ATE399007T1 (de) Raf kinase hemmer
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
NO985652L (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
ATE368466T1 (de) Androgensyntheseinhibitoren
AU2209800A (en) Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
DE69815313D1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
BR9808221A (pt) Método de tratamento de tumor.
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
BR9917113A (pt) Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
WO2000004153A3 (en) Repression of cell transformation with human pea3
EA199800058A1 (ru) Способ лечения доброкачественной гиперплазии предстательной железы, лекарственная форма для лечения доброкачественной гиперплазии, содержащая агонист мелатонина
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.